Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Urology, Shunde People's Hospital, Southern Medical University, Guangdong, China.
To develop a novel protein-anchor technology to immobilize human interleukin-2 on tumor cells to induce antitumor immunity.
Interleukin-2 surface-modified MB49 cells were prepared as a vaccine. Subcutaneous and pulmonary metastatic mouse models of MB49 bladder cancer were used to evaluate the antitumor efficiency of the vaccine. Immunohistochemistry, flow cytometric, and cytotoxic T-lymphocyte assay were performed to assess the proportion and cytotoxicity of the T lymphocytes.
The IL-2 surface-modified MB49 cell vaccine inhibited tumor growth and extended the survival of the mice, and the vaccine-cured mice effectively resisted the second MB49 but not the RM-1 prostate cancer cell challenge. Furthermore, more cytotoxicity on the MB49 cells and more CD4-positive, CD8-positive T cells appeared in the vaccine-treated group.
The results of our study have demonstrated that the human interleukin-2 surface-modified MB49 bladder cancer cell vaccine induced specific antitumor immunity and was efficient against metastatic bladder cancer.
Written by:
Zhang X, Shi X, Li J, Hu Z, Guo F, Huang X, Zhang Z, Sun P, Jing Y, Gao J, Tan W. Are you the author?
Reference: Urology. 2011 Jul 7. Epub ahead of print.
doi: 10.1016/j.urology.2011.04.044
PubMed Abstract
PMID: 21741685
UroToday.com Prostate Cancer Section
